Minerva Neurosciences Inc. (NASDAQ:NERV) stock has reached a new 52-week low, trading at $2.03, as investors show concern ...

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s ...

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company with a current market capitalization of $15.21 million, has received a conditional extension to remain listed ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...